In this issue:
Long-term recurrence risk after discontinuing anticoagulants for first unprovoked VTE
6 months vs. 2 years of oral anticoagulation after first unprovoked DVT
aHUS in the eculizumab era
Autologous SCT vs. chemotherapy alone for immunoglobulin light chain amyloidosis
Haematological recovery with eltrombopag for AA refractory or intolerant to immunosuppressants
Hypomethylating agents before allogeneic SCT in higher-risk MDS
Patient-reported outcomes for salvage autologous SCT in relapsed multiple myeloma
Bendamustine + rituximab for relapsed/refractory follicular lymphoma
Variables influencing response to venetoclax in relapsed CLL
Focal skeletal FDG uptake indicates poor prognosis in classical Hodgkin’s lymphoma
Please login below to download this issue (PDF)